LACTOLOGY FOUNDATION

Comprehensive Clinical and Pathological Spectrum of Human Thyroid Disorders: Functional Dysfunctions, Inflammatory States, and Neoplastic Stratifications

Introduction and Epidemiological Dynamics

The human thyroid gland is a central endocrine organ that regulates systemic metabolic homeostasis, cellular respiration, protein synthesis, and cardiovascular hemodynamics through the synthesized and secreted iodinated amino acids thyroxine ($T_4$) and triiodothyronine ($T_3$). Thyroid hormone production and secretion are maintained by a classic endocrine negative feedback loop involving hypothalamic thyrotropin-releasing hormone (TRH) and anterior pituitary thyroid-stimulating hormone (TSH, or thyrotropin).

Pathologies of the thyroid gland constitute the most frequent endocrine disorders met in clinical practice. These conditions encompass a broad physiological spectrum: functional abnormalities characterized by hormone deficiency (hypothyroidism) or hormone excess (thyrotoxicosis), inflammatory conditions (thyroiditis), structural dysmorphisms (goiter and nodular disease), and a complex array of benign, low-risk, and frank malignant neoplasms. Epidemiological investigations consistently document a marked female predominance across almost all thyroid pathologies, alongside a progressive rise in incidence associated with advancing age.

Data from the Third National Health and Nutrition Examination Survey (NHANES III), evaluating 17,353 non-institutionalized individuals aged 12 years and older, established foundational population-level benchmarks for thyroid dysfunction. In this cohort, hypothyroidism was present in 4.6% of the population (0.3% overt and 4.3% mild or subclinical), whereas thyrotoxicosis was detected in 1.3% (0.5% overt and 0.7% mild or subclinical). Subgroup analyses revealed that thyroid dysfunction is more prevalent in white and Mexican American populations than in Black populations. Furthermore, among individuals aged 65 years and older, overt hypothyroidism reaches a prevalence of 2%, with subclinical hypothyroidism affecting up to 14%.

Palpable thyroid nodules occur in approximately 6% of women and 2% of men in iodine-sufficient populations. However, high-resolution sonography and computed tomography (CT) reveal clinically non-palpable incidental thyroid nodules in up to 27% of adults. Conversely, diffuse non-toxic goiter has experienced a steady decline in prevalence across developed nations, reflecting widespread dietary iodine supplementation.

Thyroid carcinomas represent a major clinical focus due to their changing epidemiological profile. Currently ranking as the 14th most common malignancy in the United States, thyroid cancer exhibits an annual incidence of approximately 23,600 new cases with a 3:1 female-to-male ratio. Crucially, thyroid cancer demonstrated the fastest rising incidence rate among all solid tumors in recent decades (increasing by 3.8% annually between 1992 and 2001), largely driven by enhanced detection of early-stage sub-centimeter lesions. Because multimodal therapy yields excellent overall survival rates exceeding 95%, the population of long-term thyroid cancer survivors requiring chronic surveillance exceeds 300,000 individuals in the United States alone.

Hypothyroidism: Etiology, Pathophysiology, and Clinical Management

Hypothyroidism is a systemic metabolic state resulting from inadequate thyroid hormone action at the tissue level. Anatomically and functionally, it is classified into primary hypothyroidism, arising from intrinsic thyroid gland dysfunction, and central (secondary or tertiary) hypothyroidism, caused by impaired hypothalamic TRH or pituitary TSH secretion. Biochemically, the disease is stratified into overt hypothyroidism (elevated serum TSH with decreased serum free $T_4$) and mild/subclinical hypothyroidism (elevated serum TSH with normal free $T_4$).

The etiological spectrum of primary hypothyroidism encompasses congenital and acquired disorders. Worldwide, severe dietary iodine deficiency remains the primary cause of congenital hypothyroidism and endemic cretinism. In iodine-replete environments, congenital hypothyroidism occurs in approximately 1 in 4,000 live births. It stems predominantly from thyroid gland dysgenesis (aplasia, hypoplasia, or ectopy linked to mutations in transcription factor genes such as PAX8 and TTF1) or inherited dyshormonogenesis due to inactivating mutations in genes encoding thyroid peroxidase (TPO), the sodium-iodide symporter (NIS), or thyroglobulin (TG). Central congenital forms result from mutations in genes governing thyrotrope differentiation (POU1F1, PROP1) or structural defects in the TRH receptor, TSH $\beta$-subunit, or TSH receptor. Peripheral resistance to thyroid hormone is caused by dominant-negative mutations in the thyroid hormone receptor-$\beta$ (THRB) gene.

Acquired primary hypothyroidism is predominantly caused by chronic autoimmune thyroiditis (Hashimoto disease). Pathologically, Hashimoto disease is characterized by diffuse lymphocytic infiltration of the thyroid parenchyma, extensive follicular cell destruction, oxyphilic (oncocytic) metaplasia, germinal center formation, and fibrous replacement. Circulating autoantibodies against thyroid peroxidase (anti-TPO) and thyroglobulin (anti-Tg) are present in over 90% of affected individuals. Genetic vulnerability is polygenic, showing strong linkage to major histocompatibility complex (MHC) class II loci (HLA-DR3, HLA-DR5) and immune regulatory genes such as CTLA4 and PTPN22. Environmental triggers, including high dietary iodine intake, treatment with interferon-alpha, and immune checkpoint inhibitor therapy, can initiate or exacerbate autoimmune destruction.

Other acquired primary etiologies include iatrogenic destruction following surgical thyroidectomy, total ablation with radioactive iodine ($^{131}\text{I}$), or external beam radiation therapy for head and neck cancers. Infiltrative disorders such as systemic hemochromatosis, sarcoidosis, and fibrous Riedel thyroiditis can destroy functional parenchyma. Pharmacologic agents frequently implicated in drug-induced hypothyroidism include lithium carbonate (which inhibits thyroid hormone release), amiodarone (due to its high iodine content inducing sustained Wolff-Chaikoff blockade), thalidomide, aminoglutethimide, and antineoplastic tyrosine kinase inhibitors.

Central hypothyroidism stems from sellar or suprasellar lesions, including pituitary macroadenomas, craniopharyngiomas, neurosurgical interventions, pituitary radiation therapy, traumatic brain injury, lymphocytic hypophysitis, Sheehan syndrome (postpartum pituitary necrosis), or treatment with the retinoid X receptor agonist bexarotene.

At the cellular level, thyroid hormone actions are mediated by nuclear triiodothyronine ($T_3$) receptors bound to thyroid response elements (TREs) in target gene promoter regions. In hypothyroidism, diminished nuclear receptor occupancy alters gene transcription across target tissues. Hepatic downregulation of low-density lipoprotein (LDL) receptor expression reduces metabolic LDL clearance, producing hypercholesterolemia and hyperhomocysteinemia. In cardiac myocytes, decreased transcription of $\alpha$-myosin heavy chain ($\alpha$-MHC) and sarcoplasmic reticulum calcium-ATPase 2a ($SERCA2a$), alongside upregulation of $\beta$-MHC, impairs both systolic myocardial contraction and diastolic relaxation.

Clinical manifestations reflect generalized metabolic slowing and extracellular accumulation of glycosaminoglycans, particularly hyaluronic acid. Symptoms include chronic fatigue, lethargy, cold intolerance, modest weight gain, severe constipation, dry hyperkeratotic skin, hoarseness, memory impairment, depressed mood, and menorrhagia. Physical signs comprise sinus bradycardia, diastolic hypertension, hypothermia, periorbital and non-pitting peripheral edema (myxedema), coarse brittle hair, loss of the lateral third of the eyebrows, delayed relaxation phase of deep tendon reflexes, and pleural or pericardial effusions. Severe prolonged untreated hypothyroidism can precipitate myxedema coma, a life-threatening crisis characterized by hypothermia, severe hyponatremia, hypercapnic respiratory failure, paralysis, and cardiovascular collapse.

Laboratory confirmation relies primarily on automated serum TSH assays. In primary hypothyroidism, serum TSH is elevated above the normal reference range ($0.4\text{--}4.0\,\mu\text{U/mL}$), whereas free $T_4$ is low in overt disease and normal in subclinical disease. In central hypothyroidism, serum TSH may be low, inappropriately normal, or slightly elevated (due to circulating TSH isoforms with reduced biological activity); thus, direct measurement of free $T_4$ is mandatory whenever hypothalamic or pituitary disease is suspected. Elevated serum anti-TPO antibody titers confirm underlying Hashimoto thyroiditis.

The definitive therapy for hypothyroidism is oral synthetic levothyroxine sodium ($L\text{-}T_4$). Levothyroxine features a 7-day plasma half-life and undergoes peripheral enzymatic outer-ring deiodination to active $T_3$, maintaining stable physiological hormone pools. The standard maintenance dosage in adults without residual thyroid function is approximately $1.8\,\mu\text{g/kg/day}$. In elderly patients, whose metabolic clearance of thyroxine is diminished, starting doses should be reduced ($0.5\,\mu\text{g/kg/day}$). Therapeutic monitoring via serum TSH measurement is performed 4 to 6 weeks after initiating or altering a dose, aiming for a steady-state TSH in the lower half of the reference range ($1.0\text{--}2.0\,\mu\text{U/mL}$).

Specific clinical settings require adapted management protocols:

• Ischemic Heart Disease: Rapid restoration of euthyroidism increases myocardial oxygen demand, potentially precipitating angina or myocardial infarction. Levothyroxine is started at $12.5\text{--}25\,\mu\text{g/day}$ and titrated cautiously in small increments every 4 to 6 weeks alongside clinical and electrocardiographic monitoring.
• Pregnancy: Estrogen-induced elevations in serum thyroxine-binding globulin (TBG) and placental degradation of $T_4$ increase levothyroxine requirements by 50% to 100%. Prompt dose adjustments during gestation are critical to prevent maternal-fetal complications and neurodevelopmental deficits.
• Myxedema Coma: Requires emergency intensive care management, including intravenous loading doses of levothyroxine ($300\text{--}500\,\mu\text{g}$) or $T_3$, empirical stress-dose intravenous hydrocortisone (to treat concurrent autoimmune adrenal insufficiency), mechanical ventilatory support, and passive rewarming.

Thyrotoxicosis and Hyperthyroidism: Pathophysiology, Diagnosis, and Therapeutics

Thyrotoxicosis is defined as the clinical state resulting from elevated circulating concentrations of active thyroid hormones, regardless of source. Hyperthyroidism is a subset of thyrotoxicosis caused specifically by excess de novo synthesis and secretion of thyroid hormones by an overactive thyroid gland.

The etiologies of thyrotoxicosis are categorized by underlying mechanism into hyperthyroidism driven by abnormal gland stimulation or autonomy, unregulated release from glandular destruction (thyroiditis), and extra-thyroidal or exogenous hormone excess.

Graves disease accounts for the majority of hyperthyroid cases. It is an autoimmune disorder driven by circulating autoantibodies against the TSH receptor. These TSH receptor autoantibodies (TRAb), specifically thyroid-stimulating immunoglobulins (TSI), bind to and activate the TSH receptor, inducing follicular cell hyperplasia and unregulated hormone synthesis. Genetic predisposition is tied to HLA-B8, HLA-DR3, CTLA4 polymorphisms, and a locus on chromosome 20q11. Environmental factors, including psychological stress, cigarette smoking, high iodine intake, and viral infections, serve as triggers.

Toxic multinodular goiter (TMNG) and solitary toxic adenoma represent autonomous hyperfunctioning thyroid disorders common in older adults and iodine-deficient regions. These conditions are driven by somatic activating mutations in genes encoding the TSH receptor (TSHR) or the $G_s\alpha$ subunit (GNAS), leading to clonal follicular proliferation and autonomous hormone secretion independent of pituitary control.

Inflammatory thyrotoxicosis occurs during the early phase of subacute granulomatous thyroiditis (de Quervain) or subacute lymphocytic (silent or postpartum) thyroiditis. Mechanical and immune-mediated destruction of follicular membranes allows passive leakage of preformed stored thyroid hormone into the systemic circulation. This transient thyrotoxic state (typically lasting 2 to 8 weeks) resolves spontaneously as hormone stores deplete, often followed by a temporary hypothyroid phase prior to follicular recovery.

Amiodarone-induced thyrotoxicosis (AIT) presents in two pathophysiologically distinct forms:

• Type 1 AIT: True hyperthyroidism triggered by the drug's high iodine load in patients with underlying latent Graves disease or nodular goiter (Jod-Basedow effect).
• Type 2 AIT: Drug-induced destructive inflammatory thyroiditis causing follicular cell necrosis and uncoordinated hormone release in a previously normal gland.

Gestational or chorionic gonadotropin-mediated hyperthyroidism occurs in early pregnancy or trophoblastic disease (hydatidiform mole, choriocarcinoma). Human chorionic gonadotropin (hCG) shares structural $\alpha$-subunit homology with TSH, and at high concentrations, it cross-activates the TSH receptor. Central hyperthyroidism is rare, caused by TSH-secreting pituitary macroadenomas or selective pituitary resistance to thyroid hormone. Exogenous thyrotoxicosis stems from deliberate, accidental, or factitious ingestion of excess thyroid hormone preparations.

Clinical features reflect hypermetabolism and heightened beta-adrenergic responsiveness. Patients report weight loss despite increased appetite, heat intolerance, diaphoresis, fine hand tremor, palpitations, anxiety, insomnia, proximal muscle weakness, hyperdefecation, and oligomenorrhea. Physical signs include sinus tachycardia, systolic hypertension with widened pulse pressure, warm moist skin, palmar erythema, brisk reflexes, lid lag, and a hyperdynamic precordium with a systolic flow murmur.

Pathognomonic signs help differentiate specific causes:

• Graves disease presents with a symmetrical, non-tender, smooth goiter with an audible vascular bruit. Associated extrathyroidal manifestations include Graves orbitopathy (proptosis, periorbital edema, extraocular muscle fibrosis, conjunctival injection), pretibial myxedema (thyroid dermopathy featuring non-pitting dermal hyaluronic acid accumulation), and thyroid acropachy (digital clubbing).
• Toxic adenoma or TMNG presents as single or multiple palpable non-tender thyroid nodules.
• Subacute thyroiditis presents with a firm, exquisitely tender goiter with pain radiating to the ears and jaw, accompanied by systemic fever and an elevated erythrocyte sedimentation rate (ESR).

Establishing the etiology of thyrotoxicosis relies on serum TSH (suppressed to $<0.1\,\mu\text{U/mL}$ in primary hyperthyroidism), free $T_4$, total $T_3$, and fractional radioactive iodine uptake (RAIU) imaging. High or normal fractional RAIU indicates true hyperthyroidism with active hormone synthesis (Graves disease, toxic adenoma, TMNG). Conversely, low or absent RAIU indicates destructive thyroiditis, excess iodine, or exogenous hormone ingestion.

Therapeutic strategies for hyperthyroidism depend on etiology, disease severity, and patient comorbidities:

• Beta-Adrenergic Blockers (e.g., propranolol, atenolol): Blunt sympathetic activity to relieve tremor, palpitations, anxiety, and heat intolerance. High-dose propranolol also inhibits peripheral $T_4$-to-$T_3$ conversion.
• Thionamide Antithyroid Drugs (Methimazole, Propylthiouracil): Inhibit thyroid peroxidase, blocking organification and coupling steps in thyroid hormone synthesis. Methimazole is the primary agent due to daily dosing and a lower risk of severe hepatoxicity. Propylthiouracil (PTU) is reserved for the first trimester of pregnancy (to avoid methimazole-induced embryopathy), thyroid storm, and patients with minor reactions to methimazole. Patients must be monitored for agranulocytosis, vasculitis, and hepatic injury.
• Radioactive Iodine ($^{131}\text{I}$): Delivers targeted beta-particle radiation to induce follicular cell necrosis; serves as a definitive treatment for Graves disease, toxic adenoma, and TMNG. Post-ablative hypothyroidism is a expected outcome requiring lifelong levothyroxine.
• Surgical Thyroidectomy: Provides rapid definitive cure; indicated for large compressive goiters, suspected coexisting malignancies, severe Graves orbitopathy, or thionamide intolerance.

Thyroid storm represents a severe, life-threatening exacerbation of thyrotoxicosis characterized by hyperpyrexia, tachyarrhythmias, heart failure, delirium, and gastrointestinal failure. Emergency management requires a multimodal regimen: high-dose PTU (to block synthesis and $T_4$-to-$T_3$ conversion), oral inorganic iodine or radiocontrast agents (to inhibit hormone release via the Wolff-Chaikoff effect), intravenous glucocorticoids (to reduce $T_4$-to-$T_3$ conversion and support adrenal reserve), intravenous beta-blockers, and aggressive cooling.

Spectrum of Inflammatory Thyroid Disorders

Thyroiditis includes a pathophysiologically diverse group of inflammatory, autoimmune, infectious, and sclerosing disorders affecting the thyroid gland. Clinical presentations range from severe acute neck pain and systemic symptoms to asymptomatic goitrous enlargement or permanent thyroid dysfunction.

Autoimmune thyroiditis (Hashimoto disease) represents the chronic end-member, characterized by lymphocytic infiltration, progressive destruction of functional parenchyma, and development of anti-TPO antibodies, culminating in permanent primary hypothyroidism.

Subacute granulomatous thyroiditis (de Quervain) is a self-limiting post-viral inflammatory condition linked to HLA-B35. Histologically, it displays focal follicular destruction, microabscesses, and multinucleated giant-cell granulomas. Patients present with fever, malaise, and a hard, exquisitely painful goiter. Serum TSH is suppressed during the initial thyrotoxic release phase, accompanied by marked elevations in ESR and C-reactive protein (CRP). Treatment includes high-dose NSAIDs or systemic glucocorticoids (prednisone $40\,\text{mg/day}$) for severe pain.

Subacute lymphocytic (painless or silent) thyroiditis is an autoimmune disorder occurring sporadically or postpartum (postpartum thyroiditis). It is characterized by lymphocytic infiltration without granulomas and follows a biphasic clinical course: transient thyrotoxicosis followed by temporary hypothyroidism before spontaneous resolution. RAIU is depressed during the initial phase, distinguishing it from Graves disease.

Acute suppurative thyroiditis is a rare infectious process caused by bacterial (Staphylococcus, Streptococcus), fungal, or mycobacterial organisms. Infection typically occurs via hematogenous seeding or persistent structural anomalies, such as a piriform sinus fistula. Patients present with severe localized neck pain, erythema, warmth, fever, and leukocytosis. Management requires targeted parenteral antibiotics and surgical abscess drainage.

Riedel thyroiditis is a rare systemic IgG4-related fibro-inflammatory disease. Dense fibrous tissue replaces the thyroid parenchyma and invades adjacent neck structures (trachea, esophagus, recurrent laryngeal nerves). The gland becomes stone-hard, fixed, and painless, causing structural airway obstruction and vocal cord paralysis. Treatment involves surgical decompression of the tracheal stripe, systemic glucocorticoids, tamoxifen, or immunosuppressants.

Thyroid Follicular Nodular Disease and Benign Goitrogenesis

Goiter refers to enlargement of the thyroid gland, presenting as diffuse gland expansion or progressing over time into multinodular goiter (MNG). Worldwide, chronic dietary iodine deficiency is the main driver of goitrogenesis. When daily iodine intake falls below $50\,\mu\text{g/day}$, diminished thyroid hormone synthesis leads to compensatory elevations in pituitary TSH secretion. Sustained TSH stimulation induces follicular cell hypertrophy and hyperplasia, expanding gland volume to maximize iodine capture.

In iodine-replete populations, non-toxic goiter stems from subtle inherited dyshormonogenic defects, dietary goitrogens, or autocrine growth factors (e.g., insulin-like growth factor-1, epidermal growth factor) that induce polyclonal and monoclonal follicular proliferation. Over time, repeated cycles of hyperplasia and involution yield structural heterogeneity, fibrous scarring, cyst formation, and nodular transformation.

The 5th Edition of the World Health Organization (WHO) Classification introduced a revised diagnostic category: Thyroid Follicular Nodular Disease (FND). This term encompasses the spectrum of non-neoplastic, hyperplastic, and clonal non-invasive follicular lesions previously designated as adenomatoid nodules, colloid nodules, hyperplastic nodules, or multinodular goiters. Morphologically, FND displays multiple follicular nodules lacking complete fibrous capsules, composed of variable-sized follicles lined by cytologically bland epithelium without architectural atypia or nuclear features of papillary thyroid carcinoma. Establishing FND as a benign process avoids overdiagnosis and reduces unnecessary surgical intervention.

Clinical manifestations of goiter depend on gland volume, anatomical location, and functional status. Large substernal goiters extending into the anterior mediastinum can compress surrounding structures in the neck and thoracic inlet. Tracheal compression causes dyspnea, positional stridor, and chronic cough; esophageal compression causes dysphagia; and recurrent laryngeal nerve traction causes hoarseness. Severe thoracic outlet obstruction can produce superior vena cava syndrome, marked by facial congestion and venous engorgement when raising both arms overhead (Pemberton sign).

Diagnostic workup includes serum TSH measurement (to exclude subclinical or overt functional disease), high-resolution neck ultrasound, pulmonary flow-volume loops (to quantify upper airway narrowing), and cross-sectional non-contrast CT or MRI to define substernal extension. Iodinated contrast media should be used judiciously in patients with large multinodular goiters, as acute iodine exposure can trigger severe hyperthyroidism (Jod-Basedow effect) or delay subsequent radioiodine imaging and therapy if malignancy is detected.

Management of benign Thyroid Follicular Nodular Disease and compressive goiter includes:

• Observation with sonographic monitoring for asymptomatic non-compressive euthyroid disease.
• Surgical Thyroidectomy (total or near-total) for patients with tracheal or esophageal compression, retrosternal extension, or cosmetic concerns.
• Radioactive Iodine ($^{131}\text{I}$) administration to achieve goiter volume reduction (typically 30% to 50% within 12 months), particularly in poor surgical candidates. Pre-treatment with recombinant human TSH (rhTSH) can enhance fractional radioiodine uptake in non-toxic multinodular goiters.
• Suppressive Levothyroxine Therapy has largely been abandoned due to limited efficacy and increased risks of osteoporosis and atrial fibrillation.

Neoplastic Stratification and Pathology (WHO 5th Edition Framework)

The pathological classification of primary thyroid neoplasms was refined in the 5th Edition of the World Health Organization (WHO) Classification of Endocrine and Neuroendocrine Tumors. The framework integrates cytomorphology, histological architecture, biological behavior, and molecular alterations into a hierarchical scheme. Under this system, follicular cell-derived neoplasms are divided into three biological families: benign tumors, low-risk neoplasms, and malignant neoplasms. Terminology has also been modernized: "variant" was replaced by "subtype" to avoid confusion with genetic variants, and "Hürthle cell" was replaced by "oncocytic cell".

Benign follicular cell-derived neoplasms are solitary, encapsulated, non-invasive clonal proliferations. Follicular Thyroid Adenoma is a solitary, fully encapsulated benign tumor displaying follicular differentiation. Oncocytic Adenoma is an encapsulated tumor composed of $>75\%$ oncocytic cells (cells with abundant eosinophilic cytoplasm packed with altered mitochondria), replacing the former designation of Hürthle cell adenoma. Follicular Adenoma with Papillary Architecture is a hyperfunctioning benign tumor featuring papillary infoldings, typically presenting as a "hot" nodule on scintigraphy.

Low-risk neoplasms exhibit borderline morphological features or low malignant potential, behaving indolently following complete surgical excision. Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP) is a non-invasive, encapsulated, follicular-patterned lesion displaying nuclear features of papillary thyroid carcinoma (enlargement, overlapping, grooves, chromatin clearing). Reclassifying these tumors away from "carcinoma" helps prevent overtreatment. Genetically, NIFTPs are driven primarily by RAS point mutations. Thyroid Tumors of Uncertain Malignant Potential include Follicular Tumor of Uncertain Malignant Potential (FTUMP) and Well-Differentiated Tumor of Uncertain Malignant Potential (WDTUMP), characterized by borderline or questionable capsular/vascular invasion. Hyalinizing Trabecular Tumor (HTT) is a rare low-risk lesion featuring a trabecular growth pattern, marked intratumoral hyalinization, nuclear pseudoinclusions, and characteristic GLIS1 or GLIS3 gene fusions.

Malignant follicular cell-derived neoplasms represent a biological spectrum ranging from well-differentiated tumors to highly lethal undifferentiated carcinomas:

• Papillary Thyroid Carcinoma (PTC): The most common thyroid malignancy, defined by nuclear features including enlargement, overlapping, irregular nuclear membranes, chromatin clearing, grooves, intranuclear pseudoinclusions, and psammoma bodies. PTCs are driven by BRAF mutations (predominantly BRAF p.V600E) or RET/PTC gene fusions. Subtypes include Classical, Tall Cell ($\ge 30\%$ tall cells; aggressive clinical behavior), Columnar Cell, Solid, Diffuse Sclerosing, and Hobnail. Papillary microcarcinomas ($<1.0\,\text{cm}$) are no longer classified as a separate entity; they are subtyped according to their underlying histomorphology.
• Follicular Thyroid Carcinoma (FTC): Malignant epithelial tumor featuring follicular differentiation without PTC nuclear features. FTC is stratified by invasion depth into Minimally Invasive (capsular invasion only), Encapsulated Angioinvasive, and Widely Invasive. Genetically, FTCs are driven primarily by RAS mutations or PAX8::PPARG fusions.
• Oncocytic Carcinoma of the Thyroid: Reclassified as a distinct malignant entity composed of $>75\%$ oncocytic cells lacking PTC nuclear features or high-grade criteria. It displays higher rates of hematogenous metastasis and lower radioiodine avidity than classical PTC.
• High-Grade Follicular-Cell Derived Malignancies: Includes Poorly Differentiated Thyroid Carcinoma (PDTC; defined by Turin criteria: solid/trabecular/insular growth, absence of PTC nuclear features, and necrosis or $\ge 3$ mitoses per $10$ HPFs) and Differentiated High-Grade Thyroid Carcinoma (DHGTC). DHGTC comprises differentiated carcinomas (PTC, FTC, or Oncocytic Carcinoma) that retain differentiated cytomorphology but exhibit high-grade features ($\ge 5$ mitoses per $2\,\text{mm}^2$ or necrosis), conferring an aggressive clinical course similar to PDTC.
• Anaplastic Thyroid Carcinoma (ATC): Undifferentiated, highly lethal malignancy displaying extreme cytological pleomorphism, spindle cell, giant cell, or epithelioid growth, high mitotic activity, extensive necrosis, and frequent TP53 and TERT promoter mutations. Primary Squamous Cell Carcinoma of the thyroid is now categorized as a morphologic pattern/subtype of ATC.

C-cell derived neoplasms arise from calcitonin-secreting parafollicular C cells. Medullary Thyroid Carcinoma (MTC) is a neuroendocrine tumor secreting calcitonin and CEA. Approximately 25% of cases are hereditary (MEN 2A, MEN 2B, or familial MTC) driven by germline activating RET mutations, whereas 75% are sporadic. The 2022 WHO classification introduced a 2-tier grading system for MTC: High-grade MTC is defined by $\ge 5$ mitoses per $2\,\text{mm}^2$, tumor necrosis, or a Ki-67 index $\ge 5\%$, identifying tumors with increased risk of recurrence and mortality.

Other primary thyroid entities include Mixed Medullary and Follicular-Cell Derived Carcinomas, Salivary Gland-Type Carcinomas (Mucoepidermoid, Secretory), Thymic Tumors Within the Thyroid (SETTLE, CASTLE), Embryonal Tumors (Thyroblastoma, driven by DICER1 mutations), and Tumors of Uncertain Histogenesis (Cribriform-Morular Thyroid Carcinoma, driven by CTNNB1 mutations and associated with Familial Adenomatous Polyposis).

Cytopathology, Diagnostic Biomarkers, and the 2023 Bethesda System

Ultrasound-guided Fine-Needle Aspiration (FNA) cytology is the primary diagnostic tool for evaluating thyroid nodules. To standardize reporting, clinical management, and interdisciplinary communication, the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was updated in its 3rd Edition (2023).

The 2023 Bethesda System assigned a single standardized name to each of the six diagnostic categories, eliminating confusing alternate terms. Implied risk of malignancy (ROM) figures were recalculated based on extensive global post-2017 surgical pathology data, presenting mean ROMs and expected ranges. ROM estimates were also stratified according to whether NIFTP lesions were classified as malignancies or non-malignant low-risk neoplasms.

The six standardized 2023 Bethesda categories, their cytomorphological diagnostic criteria, recalculated ROMs, and clinical management guidelines are structured as follows:

Category I (Nondiagnostic) applies to specimens lacking minimum adequacy requirements (at least 6 clusters of well-preserved follicular cells with $\ge 10$ cells per cluster) or those obscured by blood, thick colloid, or drying artifact. The implied mean ROM is 13% (range 5–20%). Standard management requires repeating ultrasound-guided FNA with rapid on-site adequacy assessment.

Category II (Benign) displays abundant colloid with flat sheets of evenly spaced, cytologically bland follicular cells lacking nuclear atypia. This includes colloid nodules, adenomatoid nodules, Hashimoto thyroiditis, and subacute thyroiditis. The implied mean ROM is 4% (range 2–7%). Standard management involves clinical and sonographic follow-up.

Category III (Atypia of Undetermined Significance - AUS) comprises specimens exhibiting nuclear, architectural, or oncocytic atypia insufficient for higher-grade categories. The 2023 update removed the alternate term "Follicular Lesion of Undetermined Significance (FLUS)" and formalized two subcategories: AUS-nuclear atypia (associated with higher ROM and BRAF-like mutations) and AUS-other (architectural or oncocytic atypia, associated with lower ROM and RAS-like mutations). The implied mean ROM is 22% (range 13–30%). Recommended management includes repeat FNA, ancillary molecular profiling, or diagnostic lobectomy.

Category IV (Follicular Neoplasm) represents cellular aspirates composed of microfollicles, cell crowding, or oncocytic cells with reduced colloid, lacking PTC nuclear features. Formerly subcategorized as oncocytic/Hürthle cell lesions, it is now designated as Follicular Neoplasm, specifying if oncocytic type. The implied mean ROM is 30% (range 23–34%). Management involves molecular profiling or surgical lobectomy.

Category V (Suspicious for Malignancy) exhibits features strongly suggestive of malignancy (usually PTC, MTC, or lymphoma) but lacking full quantitative or qualitative criteria for definitive diagnosis. The implied mean ROM is 74% (range 67–83%). Recommended management is surgical lobectomy or total thyroidectomy.

Category VI (Malignant) displays unequivocal cytological features of malignancy, including classical PTC, poorly differentiated carcinoma, anaplastic carcinoma, medullary carcinoma, or metastatic disease. The implied mean ROM is 97% (range 97–100%). Standard management requires surgical resection tailored to tumor histology.

Integrating molecular testing panels into the evaluation of Category III (AUS) and Category IV (Follicular Neoplasm) aspirates has refined diagnostic accuracy. Next-generation sequencing (NGS) panels (e.g., ThyroSeq v3) and gene expression classifiers (e.g., Afirma GSC) assess point mutations (BRAF, KRAS, HRAS, NRAS, TERT promoter, RET, TP53), gene fusions (RET/PTC, PAX8::PPARG, NTRK1/3, ALK), and copy-number alterations. Identifying a high-risk BRAF p.V600E or TERT promoter mutation confers a positive predictive value for malignancy approaching 100%, guiding primary total thyroidectomy. Conversely, negative molecular test results in indeterminate aspirates reduce the post-test risk of malignancy to $<5\%$, allowing safe clinical observation.

Therapeutic Management of Malignant Thyroid Neoplasms

The management of differentiated thyroid carcinomas (PTC, FTC, and Oncocytic Carcinoma) involves a multimodal strategy combining risk-stratified surgical resection, radioactive iodine ($^{131}\text{I}$) therapy, TSH-suppressive levothyroxine, and long-term surveillance.

Surgical resection remains the definitive primary treatment. Total or near-total thyroidectomy is indicated for tumors $>4\,\text{cm}$, gross extrathyroidal extension, clinically detectable cervical lymph node metastases, or high-risk histological subtypes. Unilateral total lobectomy is sufficient for low-risk unifocal intra-thyroidal carcinomas measuring $<1.0\text{--}4.0\,\text{cm}$ without nodal involvement or prior radiation exposure. Therapeutic central (Level VI) and lateral (Levels II-V) neck dissections are performed when metastatic lymphadenopathy is identified preoperatively or intraoperatively.

Postoperative Radioactive Iodine ($^{131}\text{I}$) therapy serves three distinct clinical indications:

• Remnant Ablation: Eradicating residual normal thyroid tissue to facilitate post-treatment surveillance using serum thyroglobulin measurements and diagnostic radioiodine scans.
• Adjuvant Therapy: Destroying suspected microscopic residual disease in intermediate- or high-risk tumors.
• Radioiodine Therapy: Treating persistent, recurrent, or distant metastatic iodine-avid disease (e.g., pulmonary or skeletal metastases).

Effective thyroidal uptake of $^{131}\text{I}$ requires an elevated serum TSH ($>30\,\mu\text{U/mL}$). This state can be induced either by levothyroxine withdrawal (causing transient overt hypothyroidism) or by administering intramuscular recombinant human TSH (rhTSH, thyrotropin alfa) on two consecutive days prior to radioiodine administration, avoiding hypothyroid symptoms.

Postoperative levothyroxine suppression therapy is maintained to replace thyroid hormone requirements and suppress pituitary TSH secretion below normal reference limits, blunting TSH-driven tumor growth. In high-risk patients with persistent disease, target serum TSH is suppressed to $<0.1\,\mu\text{U/mL}$. In low-risk patients achieving complete biochemical and structural remission, target TSH is maintained in the lower-normal reference range ($0.5\text{--}2.0\,\mu\text{U/mL}$) to avoid long-term risks of osteopenia and atrial fibrillation.

Surveillance relies on serial serum thyroglobulin (Tg) quantification (measured alongside serum anti-thyroglobulin antibodies to exclude immunoassay interference), high-resolution neck ultrasound, diagnostic radioiodine scans, and cross-sectional imaging. In patients with elevated serum thyroglobulin but negative radioiodine scans, Positron Emission Tomography / Computed Tomography using $^{18}\text{F}$-fluorodeoxyglucose ($^{18}\text{F}$-FDG PET/CT) is valuable for localizing dedifferentiated, non-iodine-avid recurrent tumor deposits.

For advanced, progressive, radioiodine-refractory differentiated thyroid carcinomas, medullary carcinomas, and anaplastic carcinomas, systemic targeted kinase therapies are used. Multi-kinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR), RET, and BRAF pathways—including lenvatinib, sorafenib, cabozantinib, and vandetanib—demonstrate significant progression-free survival gains. Selective BRAF inhibitors (dabrafenib combined with trametinib) offer targeted activity in BRAF p.V600E-mutated anaplastic thyroid carcinomas.

Conclusions

Human thyroid disorders represent a broad clinical and pathological spectrum, spanning functional dysfunctions, inflammatory diseases, structural goitrogenesis, and primary neoplasms. Advances in cellular pathology and molecular genetics have redefined disease classification. Integrating the 2022 World Health Organization classification with the 2023 Bethesda System provides a precise, risk-stratified framework that links cytopathology, histomorphology, and molecular profiling directly to individual patient management.